Immunotherapy for gastric cancers: emerging role and future perspectives.

Abstract:

INTRODUCTION:The broad use of immunotherapy is revolutionizing the treatment paradigms of many solid tumors. Although chemotherapy remains the treatment backbone for advanced gastric cancer, improvements in its molecular characterization and progresses in understanding its underpinning biology have supported clinical development of novel immunotherapies. However, the results of recent trials testing these new agents raise the question on how to identify the patients that could greatly benefit. Areas covered: This article summarizes the current understanding on the biology and the mechanisms underlying different clinical features of gastric cancers. Particularly, after a comprehensive literature search, we speculate whether specific molecular subsets of patients could derive more benefit from immunotherapy. Expert commentary: Most cancers may evade the immune response, which is normally regulated by a delicate balance between activating and inhibitory signals. For example, both CTLA-4 and PD-1, once linked to PD-L1/2, may inhibit T-cell signaling. The use of agent to harness the power of the immune system appears to be the ultimate frontier in gastric cancer treatment. While anti-CTLA-4 antibodies are minimally active, there is growing evidence for the efficacy of PD1/-L1 inhibitors. The search of predictive factors for immunotherapy will provide key hints towards the optimal use of these agents.

authors

Bonotto M,Garattini SK,Basile D,Ongaro E,Fanotto V,Cattaneo M,Cortiula F,Iacono D,Cardellino GG,Pella N,Fasola G,Antonuzzo L,Silvestris N,Aprile G

doi

10.1080/17512433.2017.1313113

subject

Has Abstract

pub_date

2017-06-01 00:00:00

pages

609-619

issue

6

eissn

1751-2433

issn

1751-2441

journal_volume

10

pub_type

杂志文章,评审
  • Adverse reactions to oncologic drugs: spontaneous reporting and signal detection.

    abstract::Oncology is one of the areas of medicine with the most active research being conducted on new drugs. New pharmacological entities frequently enter the clinical arena, and therefore, the safety profile of anticancer products deserves continuous monitoring. However, only very severe and (unusual) suspected adverse drug ...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1586/17512433.2015.974555

    authors: Tuccori M,Montagnani S,Capogrosso-Sansone A,Mantarro S,Antonioli L,Fornai M,Blandizzi C

    更新日期:2015-01-01 00:00:00

  • Is single versus combination therapy problematic in the treatment of cutaneous melanoma?

    abstract::Introduction: The development of immunotherapies and targeted therapies has changed the treatment approach in resectable, nonresectable, and metastatic melanoma. Because of their different pharmacological profiles, immunotherapies and/or targeted therapies have been studied in various combinations.Areas covered: We re...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1080/17512433.2019.1650641

    authors: Krattinger R,Ramelyte E,Dornbierer J,Dummer R

    更新日期:2020-03-19 00:00:00

  • Inflammation-mediated changes in drug transporter expression/activity: implications for therapeutic drug response.

    abstract::Inflammation plays a critical role in host defense, maintaining cellular and tissue integrity following chemical, physical and biological insults. Inflammation presents in a variety of acute and chronic disease states and can contribute to disease resolution or progression depending upon the type, magnitude and durati...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1586/ecp.11.66

    authors: Cressman AM,Petrovic V,Piquette-Miller M

    更新日期:2012-01-01 00:00:00

  • Radical metastasectomy followed by sorafenib versus observation in patients withclear cell renal cell carcinoma: extended follow -up of efficacy results from the randomized phase II RESORT trial.

    abstract::Background: The RESORT trial showed no longer relapse free survival (RFS) with sorafenib following radical metastasectomy in metastatic renal cell carcinoma. We present the updated 42-month follow-up data. Methods: The phase II RESORT trial randomized patients to sorafenib or observation within 12 weeks from surgery. ...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1080/17512433.2021.1879639

    authors: Mennitto A,Verzoni E,Cognetti F,Miceli R,Milella M,Mosca A,Chiuri VE,Bearz A,Morelli F,Ortega C,Atzori F,Donini M,Claps M,Guadalupi V,Sepe P,Cappelletti V,de Braud FG,Procopio G

    更新日期:2021-01-31 00:00:00

  • Pharmacodynamics of TNF-α inhibitors in psoriasis.

    abstract::Over the last two decades, research developments have revolutionized our understanding of the pathogenesis of psoriasis and of the contribution of several cytokines in the manifestation of the disease. The key role of TNF-α in the pathogenesis of psoriasis has been extensively studied and its therapeutic action, initi...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1586/ecp.11.28

    authors: Vergou T,Moustou AE,Sfikakis PP,Antoniou C,Stratigos AJ

    更新日期:2011-07-01 00:00:00

  • Novel Therapies for Thyroid Autoimmune Diseases.

    abstract::C-X-C chemokine receptor (CXCR)3 and its interferon(IFN)γ-dependent chemokines (CXCL10, CXCL9, CXCL11) are implicated in the immune-pathogenesis of autoimmune thyroiditis (AT), Graves disease (GD) and Graves Ophthalmopathy (GO). In tissue, recruited Th1 lymphocytes produce IFNγ, enhancing the tissue secretion of IFNγ-...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1586/17512433.2016.1157468

    authors: Fallahi P,Ferrari SM,Elia G,Nasini F,Colaci M,Giuggioli D,Vita R,Benvenga S,Ferri C,Antonelli A

    更新日期:2016-06-01 00:00:00

  • Sodium-glucose co-transporter-2 inhibitors as add-on therapy to insulin: rationale and evidences.

    abstract::Sodium-glucose co-transporter-2 inhibitors (SGLT-2I) are recently approved class of anti-hyperglycaemic agents for the treatment of type 2 diabetes mellitus (T2DM). SGLT-2I inhibits renal glucose reabsorption, thereby ensuing urinary glucose excretion in a dose-dependent manner. This caloric loss and osmotic diuresis,...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1586/17512433.2016.1131121

    authors: Singh AK,Singh R

    更新日期:2016-01-01 00:00:00

  • Levonorgestrel-releasing intrauterine system (LNG-IUS 12) for prevention of pregnancy for up to five years.

    abstract:INTRODUCTION:A new five-year low dose, smaller-framed, levonorgestrel-releasing intrauterine contraceptive system (LNG-IUS 12) has been introduced to complement the currently available systems. Areas Covered: This article will provide an overview of this new intrauterine system - its composition and its mechanisms of a...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1080/17512433.2017.1341308

    authors: Nelson AL

    更新日期:2017-08-01 00:00:00

  • JAK3-selective inhibitor peficitinib for the treatment of rheumatoid arthritis.

    abstract::Introduction: Rheumatoid arthritis (RA) is a chronic progressive autoimmune disease characterized by synovitis as well as symmetric and destructive arthropathy. Although several disease modified antirheumatic-drugs (DMARDs) have widely used in clinical practice, certain patients are nonresponsive to or cannot take suc...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1080/17512433.2019.1615443

    authors: Qiu Q,Feng Q,Tan X,Guo M

    更新日期:2019-06-01 00:00:00

  • Pharmacological resources, diagnostic approach and coordination of care in joint hypermobility-related disorders.

    abstract:INTRODUCTION:Joint hypermobility (JH) is the hallmark of many hereditary soft connective tissue disorders, including Ehlers-Danlos syndromes and related disorders, disorders of the TGFβ-pathway, lateral meningocele syndrome, arterial tortuosity syndrome, and cutis laxa syndromes. Contemporary practice separates individ...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1080/17512433.2018.1497973

    authors: Baban A,Castori M

    更新日期:2018-07-01 00:00:00

  • VEGF-targeted therapy and beyond: pharmacotherapy and emerging treatments in agerelated macular degeneration.

    abstract::Treatment of age-related macular degeneration (AMD) has changed dramatically over the last decade. It has evolved from primarily destructive therapies (laser-based treatment strategies) to nondestructive therapies (intravitreal pharmacotherapies that target angiogenesis). Intermittent intravitreal ranibizumab, an inhi...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1586/ecp.10.6

    authors: McGimpsey SJ,Chakravarthy U

    更新日期:2010-03-01 00:00:00

  • Pharmacokinetic drug-drug interactions with methotrexate in oncology.

    abstract::Methotrexate is an antifolate agent used in the treatment of various cancers and some autoimmune diseases. In oncology, methotrexate is frequently administered at a high dose (>1 g/m(2)) and comes with various procedures to reduce the occurrence of toxicity and particularly to ensure optimal renal elimination. Drug-dr...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1586/ecp.11.57

    authors: Levêque D,Santucci R,Gourieux B,Herbrecht R

    更新日期:2011-11-01 00:00:00

  • Assessing pharmacological interventions for bone metastases: the need for more patient-centered outcomes.

    abstract::Bone metastases are associated with a broad spectrum of clinical sequelae. Pain, reduced mobility, skeletal complications and treatment-related events reduce quality of life. Numerous randomized controlled trials have evaluated pharmacological interventions to treat bone metastases. The primary outcomes used have evol...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1586/ecp.12.21

    authors: Ford JA,Mowatt G,Jones R

    更新日期:2012-05-01 00:00:00

  • Anti-inflammatory strategies in the treatment of schizophrenia.

    abstract::Schizophrenia is a major mental illness with a lifetime prevalence of about 1%. Antipsychotic drugs, with a primary mechanism of action that involves dopamine receptor blockade, are the mainstay in the treatment of the disorder. However, despite optimum antipsychotic treatment, few patients return to pre-morbid levels...

    journal_title:Expert review of clinical pharmacology

    pub_type: 社论

    doi:10.1586/17512433.2016.1095086

    authors: Andrade C

    更新日期:2016-01-01 00:00:00

  • Cemiplimab-rwlc as first and only treatment for advanced cutaneous squamous cell carcinoma.

    abstract::Introduction: In September of 2018, the United States Federal Drug Administration (FDA) approved cemiplimab-rwlc (Libtayo) for advanced cutaneous squamous cell carcinoma (CSCC). Cemiplimab is an intravenous human monoclonal antibody directed against programmed cell death-1 receptor (PD-1). Cemiplimab blocks T-cell ina...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1080/17512433.2019.1665026

    authors: Ahmed SR,Petersen E,Patel R,Migden MR

    更新日期:2019-10-01 00:00:00

  • A meta-analysis of apremilast on psoriatic arthritis long-term assessment of clinical efficacy (PALACE).

    abstract::The aim of this article was to assess the efficacy and safety of apremilast in treatment of psoriatic arthritis (PsA) with meta-analysis method. We included four randomized clinical trials identified from MEDLINE, EMBASE, Cochrane Library, "ISRCTN Register" and "ClinicalTrials.gov" which compared apremilast with place...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,meta分析,评审

    doi:10.1586/17512433.2016.1159130

    authors: Qu X,Zhang S,Tao L,Song Y

    更新日期:2016-06-01 00:00:00

  • Brimonidine tartrate for the treatment of facial flushing and erythema in rosacea.

    abstract::Rosacea is a chronic inflammatory dermatologic condition that can often be disfiguring with significant negative impact on patients' quality of life. Sanrosa (brimonidine tartate) is a novel therapeutic agent targeting the facial flushing and erythema of rosacea through its α₂ adrenergic receptor agonist activity. The...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1586/17512433.2014.945910

    authors: Tong LX,Moore AY

    更新日期:2014-09-01 00:00:00

  • New problems arising from old drugs: second-generation effects of acetaminophen.

    abstract::Acetaminophen (APAP)/paracetamol is one of the most commonly used over-the-counter drugs taken worldwide for treatment of pain and fever. Although considered as safe when taken in recommended doses not higher than 4 g/day, APAP overdose is currently the most important cause of acute liver failure (ALF). ALF may requir...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1586/17512433.2014.944502

    authors: Tiegs G,Karimi K,Brune K,Arck P

    更新日期:2014-09-01 00:00:00

  • Three-month paliperidone palmitate - a new treatment option for schizophrenia.

    abstract:INTRODUCTION:Long-acting injectable antipsychotics (LAIAs) were introduced to improve treatment adherence and tolerability of oral formulations. After risperidone was introduced as the first long-acting injectable second-generation antipsychotic, during the last five years olanzapine pamoate, once-monthly paliperidone ...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1080/17512433.2016.1191945

    authors: Bernardo M,Bioque M

    更新日期:2016-07-01 00:00:00

  • Once-daily glycopyrronium via the Breezhaler® device for the treatment of COPD: pharmacological and clinical profile.

    abstract::In the management of chronic obstructive pulmonary disease (COPD), there is an unmet medical need for effective bronchodilator treatments that not only have a fast onset of action, but also a long duration of action and are delivered using a simple, easy-to-use device. Long-acting muscarinic antagonists such as glycop...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1586/17512433.2013.828419

    authors: Molimard M,D'Andrea P

    更新日期:2013-09-01 00:00:00

  • Lipid-based delivery of CpG oligodeoxynucleotides for cancer immunotherapy.

    abstract::The anti-tumor activity of CpG-containing oligodeoxynucleotides (ODNs) has been well established in numerous animal models and confirmed in a number of early clinical trials. While the use of chemical modifications has effectively reduced the sensitivity of ODNs to nuclease degradation and a number of human trials hav...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1586/17512433.2.2.181

    authors: Wilson KD,Tam YK

    更新日期:2009-03-01 00:00:00

  • The role of xenobiotic-metabolizing enzymes in the placenta: a growing research field.

    abstract::Introduction: The placenta is a temporary and unique organ that allows for the physical connection between a mother and fetus; this organ regulates the transport of gases and nutrients mediating the elimination of waste products contained in the fetal circulation. The placenta performs metabolic and excretion function...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1080/17512433.2020.1733412

    authors: Blanco-Castañeda R,Galaviz-Hernández C,Souto PCS,Lima VV,Giachini FR,Escudero C,Damiano AE,Barragán-Zúñiga LJ,Martínez-Aguilar G,Sosa-Macías M

    更新日期:2020-03-01 00:00:00

  • Novel disease-modifying therapeutics for the treatment of Alzheimer's disease.

    abstract::Alzheimer's disease is the most common cause of dementia and is becoming a global health concern. Despite a well-established understanding of the molecular mechanism involved in its pathogenesis, and millions of dollars of investment in drug discovery and clinical trials, no single molecule has yet been approved for i...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1586/17512433.2013.811237

    authors: Léger GC,Massoud F

    更新日期:2013-07-01 00:00:00

  • Daunorubicin and cytarabine for certain types of poor-prognosis acute myeloid leukemia: a systematic literature review.

    abstract:INTRODUCTION:Induction chemotherapy based on anthracyclines and cytarabine (Ara-C) combination remains the standard of care for acute myeloid leukemia (AML) patients who are considered candidate for intensive and curative approaches. However, the toxicity of this regimen is high, with disappointing clinical outcomes am...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1080/17512433.2019.1573668

    authors: Megías-Vericat JE,Martínez-Cuadrón D,Sanz MÁ,Poveda JL,Montesinos P

    更新日期:2019-03-01 00:00:00

  • Evolution of diagnostic approaches in betalactam hypersensitivity.

    abstract:INTRODUCTION:Betalactams are the most widely used drugs against infections and the primary cause of antibiotic hypersensitivity reactions. Reaction patterns for different betalactams have been changing in accordance with consumption trends, and vary among countries. As a consequence, in vivo and in vitro tests have had...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1080/17512433.2017.1313110

    authors: Fernandez TD,Mayorga C,Salas M,Barrionuevo E,Posadas T,Ariza A,Laguna JJ,Moreno E,Torres MJ,Doña I,Montañez MI

    更新日期:2017-06-01 00:00:00

  • Strategies for recombinant production of antimicrobial peptides with pharmacological potential.

    abstract:INTRODUCTION:The need to develop new drugs for the control of pathogenic microorganisms has redoubled efforts to prospect for antimicrobial peptides (AMPs) from natural sources and to characterize its structure and function. These molecules present a broad spectrum of action against different microorganisms and frequen...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1080/17512433.2020.1764347

    authors: Sampaio de Oliveira KB,Leite ML,Rodrigues GR,Duque HM,da Costa RA,Cunha VA,de Loiola Costa LS,da Cunha NB,Franco OL,Dias SC

    更新日期:2020-04-01 00:00:00

  • Children in clinical trials: towards evidence-based pediatric pharmacotherapy using pharmacokinetic-pharmacodynamic modeling.

    abstract:INTRODUCTION:In pediatric pharmacotherapy, many drugs are still used off-label, and their efficacy and safety is not well characterized. Different efficacy and safety profiles in children of varying ages may be anticipated, due to developmental changes occurring across pediatric life. AREAS COVERED:Beside pharmacokine...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1080/17512433.2016.1198256

    authors: Brussee JM,Calvier EA,Krekels EH,Välitalo PA,Tibboel D,Allegaert K,Knibbe CA

    更新日期:2016-09-01 00:00:00

  • Pegloticase and the patient with treatment-failure gout.

    abstract::Gout is an inflammatory arthritis characterized by sudden, painful inflammation. Gout can affect any joint in an asymmetric distribution. Gouty attacks may be isolated or can be followed by years of recurrent flares. Over time, elevated serum urate levels and tophaceous deposits can lead to deformity and disability fr...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1586/ecp.12.48

    authors: Dave AJ,Kelly VM,Krishnan E

    更新日期:2012-09-01 00:00:00

  • The adverse pharmacology of calcineurin inhibitors and their impact on hepatitis C recurrence after liver transplantation: implications for clinical practice.

    abstract::Calcineurin inhibitors are widely used as maintenance immunosuppressants in solid-organ transplantation to minimize the risk of allograft rejection. Although the use of these agents has transformed the outcomes for patient and graft survival, this has come at a cost, notably the well-known adverse events of nephrotoxi...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1586/ecp.12.49

    authors: Garcia-Saenz-de-Sicilia M,Mukherjee S

    更新日期:2012-09-01 00:00:00

  • Gemtuzumab ozogamicin for the treatment of acute myeloid leukemia.

    abstract:INTRODUCTION:Gemtuzumab ozogamicin (GO) is an antibody-drug conjugate consisting of a monoclonal antibody targeting CD33 linked to a cytotoxic derivative of calicheamicin. Despite the known clinical efficacy in relapsed/refractory acute myeloid leukemia (AML), GO was withdrawn from the market in 2010 due to increased e...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1080/17512433.2018.1478725

    authors: Baron J,Wang ES

    更新日期:2018-06-01 00:00:00